BridgeMD
MAGNEFFICIENT: A prospective, randomized, double-blind, placebo-controlled, single-center clinical trial.
EU CTIS ID: 2025-522839-33-00
What this study is testing
To determine whether 8-day oral magnesium aspartate (243 mg/day) reduces chronic postoperative hypoparathyroidism at 6 months.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adults aged 18–90 years scheduled for total thyroidectomy.
- With or without lymph node dissection, for any benign or malignant indication.
- Able to provide written informed consent.
- No history of parathyroid disorder or calcium/magnesium metabolism disorder.
You likely can't join if
- Pre-existing hypoparathyroidism or hyperparathyroidism.
- Renal insufficiency (eGFR <60 mL/min).
- Active malabsorption syndromes.
- Current or chronic use of magnesium supplementation.
- Medications affecting calcium/magnesium (e.g., diuretics).
- Known intolerance to magnesium therapy.
See the full eligibility criteria
- Adults aged 18–90 years scheduled for total thyroidectomy.
- With or without lymph node dissection, for any benign or malignant indication.
- Able to provide written informed consent.
- No history of parathyroid disorder or calcium/magnesium metabolism disorder.
- Pre-existing hypoparathyroidism or hyperparathyroidism.
- Renal insufficiency (eGFR <60 mL/min).
- Active malabsorption syndromes.
- Current or chronic use of magnesium supplementation.
- Medications affecting calcium/magnesium (e.g., diuretics).
- Known intolerance to magnesium therapy.
- Unwillingness to comply with study visits or procedures.
- Patients with comorbidities potentially exacerbated by magnesium supplementation, including: • Cardiac arrhythmias (e.g., AV block, bradyarrhythmias) • Myasthenia gravis • Severe gastrointestinal disorders affecting absorption (e.g., active IBD) • History of hypermagnesemia or magnesium toxicity • Concurrent use of medications with known magnesium interactions (e.g., aminoglycosides, digoxin, bisphosphonates, proton pump inhibitors).
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.